Amgen Inc. (NASDAQ:AMGN) Shares Bought by Silvia Mccoll Wealth Management LLC

Silvia Mccoll Wealth Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 13.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,652 shares of the medical research company’s stock after acquiring an additional 423 shares during the quarter. Amgen makes up approximately 0.8% of Silvia Mccoll Wealth Management LLC’s portfolio, making the stock its 29th biggest position. Silvia Mccoll Wealth Management LLC’s holdings in Amgen were worth $973,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AMGN. Claro Advisors LLC grew its position in shares of Amgen by 118.6% during the first quarter. Claro Advisors LLC now owns 4,691 shares of the medical research company’s stock worth $1,334,000 after buying an additional 2,545 shares in the last quarter. Talbot Financial LLC grew its position in shares of Amgen by 1.1% during the first quarter. Talbot Financial LLC now owns 38,944 shares of the medical research company’s stock worth $11,073,000 after buying an additional 440 shares in the last quarter. Miracle Mile Advisors LLC grew its position in shares of Amgen by 6.6% during the first quarter. Miracle Mile Advisors LLC now owns 4,914 shares of the medical research company’s stock worth $1,397,000 after buying an additional 303 shares in the last quarter. BKM Wealth Management LLC grew its position in shares of Amgen by 16.9% during the first quarter. BKM Wealth Management LLC now owns 5,928 shares of the medical research company’s stock worth $1,685,000 after buying an additional 855 shares in the last quarter. Finally, Aviance Capital Partners LLC lifted its stake in Amgen by 33.5% during the first quarter. Aviance Capital Partners LLC now owns 31,496 shares of the medical research company’s stock worth $8,955,000 after purchasing an additional 7,910 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN stock traded down $1.44 on Monday, reaching $311.01. 1,768,651 shares of the company’s stock were exchanged, compared to its average volume of 2,783,121. The stock has a fifty day moving average of $301.56 and a 200-day moving average of $292.30. Amgen Inc. has a twelve month low of $218.44 and a twelve month high of $329.72. The firm has a market cap of $166.84 billion, a PE ratio of 44.36, a P/E/G ratio of 2.82 and a beta of 0.58. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the prior year, the company posted $3.98 earnings per share. Amgen’s quarterly revenue was up 22.0% on a year-over-year basis. As a group, equities analysts predict that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AMGN shares. Argus boosted their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Morgan Stanley boosted their target price on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $307.35.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.